Oppenheimer Maintains Outperform Rating and $76 PT on Sarepta Therapeutics (SRPT) Following In-line FY17 Sales Guidance Estimates
Tweet Send to a Friend
Oppenheimer and Co. analyst Hartaj Singh reiterates Outperform rating and $76 price target on Sarepta Therapeutics (NASDAQ: SRPT), as the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
